Study drug is first to help patients with recurrent low-grade ovarian cancer
Low-grade serous ovarian cancer is less common and aggressive than the high-grade variety, yet exceptionally difficult to treat when frontline therapy fails.
"After surgery, with or without pre-surgical chemotherapy, when low-grade serous ovarian cancer persists or returns, chemotherapy and hormonal therapy are relatively ineffective," said David Gershenson, M.D., professor in The University of Texas MD Anderson Cancer Center Department of Gynecological Oncology and Reproductive Medicine.
Response rates for treatment are measured in single digits. Gershenson and colleagues have spent the greater part of 20 years characterizing the disease, which makes up 10 percent of ovarian cancer cases, and searching for new ways to treat it. Cancer recurs or persists in 80 to 85 percent of patients.
A phase II clinical trial by the National Cancer Institute's Gynecological Oncology Group provides the first evidence of a drug that shows a relatively high response rate for these patients.
Selumetinib halts growth or shrinks tumors
In the first-targeted therapy clinical trial for low-grade serous ovarian cancer, eight of 52 (15 percent) patients had a complete or objective partial response (tumor shrinkage) and 34 (65 percent) had no disease progression during the two-year course of the study. Study results appear in the February edition of The Lancet Oncology.
"These are remarkably encouraging results for what can ultimately be a devastating disease," said Gershenson, the paper's senior author.
These patients have a median overall survival of 80 months, about twice as long as those with high-grade disease, who are typically in their 60s when diagnosed and comprise 90 percent of ovarian cancer patients. The average age of women with low-grade cancer falls in the early 40s, Gershenson said, and it's not uncommon to see women in their 20s, 30s and 40s and the occasional teenager with the disease.
High-grade serous ovarian cancer is susceptible to chemotherapy upon relapse or recurrence.
Median overall survival not reached
Cancer-causing genetic mutations in BRAF and KRAS genes occur more frequently in low-grade ovarian cancer, so the researchers chose a drug that targets the molecular network that includes those genes.
Selumetinib inhibits MEK1/2, a critical molecule in what's known as the MAPK pathway, which includes BRAF and KRAS.
All 52 patients had received at least one previous therapy, with 30 having had three or more. Clinical trial results with selumetinib include:
- Median progression-free survival of 11 months and 34 patients (65 percent) went at least six months without their disease worsening.
- Two-year overall survival of 55 percent.
- Median overall survival had not been reached, because more than half of patients (61 percent) remained alive at the time of data cutoff for the study.
- No treatment-related deaths.
Researchers obtained tumor samples sufficient for DNA analysis from 34 patients. While 14 patients had KRAS mutations and two had BRAF mutations, there was no connection between having those mutations and whether the patients responded to selumetinib.
Gershenson said researchers will further explore the question of matching drug to mutation during a larger phase 2/3 clinical trial that he will lead with investigators from the NCI Gynecological Oncology Group and the United Kingdom. The study will enroll 250 patients and is likely to begin later this summer.
Phase 2 trials generally do not include a control or comparison group, but the team noted treatment results for 58 women not in the trial who were treated at MD Anderson with current options. Between them, these patients received 108 different chemotherapy regimens, which produced one complete and three partial responses for an overall response rate of 3.7 percent.
A step toward personalized therapy for ovarian cancer
In an accompanying commentary, Sven Mahner, M.D., and Jacobus Pfisterer, M.D., Ph.D., German oncologists who did not participate in the research, note that the study is a step toward individualized treatment for ovarian cancer that reflects important molecular differences between low-grade and high-grade disease.
The response rate and disease stabilization rate are "particularly promising in a setting of heavily pretreated recurrent disease."
"A strength of the study is mandatory reference pathology of recurrent disease to ensure exclusion of patients with progression to high-grade disease, who are likely to benefit from chemotherapy, and recurrent borderline ovarian tumors that have excellent prognosis with salvage surgery alone," Mahner and Pfisterer wrote.
Journal reference: Lancet Oncology
Provided by University of Texas M. D. Anderson Cancer Center
- Recurrent low-grade carcinoma of the ovary less responsive to chemo than more common ovarian cancers Mar 10, 2008 | not rated yet | 0
- Combined molecular-targeted and hormonal therapies offer promise in treating ovarian cancer May 08, 2007 | not rated yet | 0
- New drug combination slows tumor growth for recurrent ovarian cancer Jun 06, 2011 | not rated yet | 0
- Ashkenazi ovarian cancer patients with BRCA mutations live longer than those with normal gene Jan 02, 2008 | not rated yet | 0
- Drug cocktail boosts ovarian cancer survival time Jun 02, 2012 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Why is zone 1 in liver more prone to ischemic injury?
May 23, 2013 Hi, Is it because around central vein, there is only deoxygenated blood from the vein where as in the periphery there is hepatic artery. Also why...
How can there be villous adenoma in colon, if there are no villi there
May 22, 2013 As title suggest. Thanks :smile:
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013 Hello everyone, Ok Stomach's normal epithelium is simple columnar, now in intestinal type of adenocarcinoma of stomach it undergoes "intestinal...
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
- More from Physics Forums - Medical Sciences
More news stories
The British Menopause Society and Women's Health Concern have today released updated guidelines on Hormone Replacement Therapy (HRT) to provide clarity around the role of HRT, the benefits and the risks. The new guidelines ...
Cancer 1 hour ago | not rated yet | 0
Breast cancer characterized as "triple negative" carries a poor prognosis, with limited treatment options. In some cases, chemotherapy doesn't kill the cancer cells the way it's supposed to. New research from Western University ...
Cancer 12 hours ago | 5 / 5 (3) | 0
Mayo Clinic researchers have used next generation genomic analysis to determine that some of the more aggressive prostate cancer tumors have similar genetic origins, which may help in predicting cancer progression. The findings ...
Cancer 12 hours ago | not rated yet | 0
Even while being dragged to its destruction inside a cell, a cancer-promoting growth factor receptor fires away, sending signals that thwart the development of tumor-suppressing microRNAs (miRNAs) before it's dissolved, researchers ...
Cancer 13 hours ago | not rated yet | 0 |
Treating pediatric leukemia patients with a liposomal formulation of anthracycline-based chemotherapy at a more intense-than-standard dose during initial treatment may result in high survival rates without causing any added ...
Cancer 17 hours ago | not rated yet | 0
(Medical Xpress)—Regulating the distribution of power in neurons is done by a system that makes the national electric grid look simple by comparison. Each neuron has several thousand mitochondria confined ...
12 hours ago | 4.8 / 5 (6) | 0 |
A brief visual task can predict IQ, according to a new study. This surprisingly simple exercise measures the brain's unconscious ability to filter out visual movement. The study shows that individuals whose ...
17 hours ago | 4.5 / 5 (10) | 1 |
Teams of highly respected Alzheimer's researchers failed to replicate what appeared to be breakthrough results for the treatment of this brain disease when they were published last year in the journal Science.
15 hours ago | 5 / 5 (1) | 2 |
Scientists at the National Institutes of Health report they have discovered in mouse studies that a small molecule released in the spinal cord triggers a process that is later experienced in the brain as ...
15 hours ago | 5 / 5 (2) | 0 |
Little is known about why asthma develops, how it constricts the airway or why response to treatments varies between patients. Now, a team of researchers at Weill Cornell Medical College, Columbia University Medical Center ...
16 hours ago | not rated yet | 0 |
Ethnic background plays a surprisingly large role in how diabetes develops on a cellular level, according to two new studies led by researchers at the Stanford University School of Medicine.
13 hours ago | not rated yet | 0 |